{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.36","upperLimit":"11.83","value":"10.4"},{"groupId":"OG001","lowerLimit":"6.31","upperLimit":"8.31","value":"7.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"190"},{"groupId":"OG001","value":"139"}],"units":"Participants"}],"description":"Duration of OR was analyzed in the subset of patients who achieved an OR. The duration of OR was defined as the time from the initial CR or PR until documented PD or death. Lesions were assessed by computed tomography (CT), magnetic resonance imaging (MRI), or ultrasound every 9 weeks.","dispersionType":"95% Confidence Interval","groups":[{"description":"Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m\\^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Bevacizumab 15 mg/kg was administered IV on Day 1 of each of the six 21-day treatment cycles. The bevacizumab dose was based on the patient's weight at baseline and remained the same throughout the study.","id":"OG000","title":"Carboplatin and Gemcitabine + Bevacizumab"},{"description":"Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m\\^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Placebo was administered by IV on Day 1 of each of the six 21-day treatment cycles.","id":"OG001","title":"Carboplatin and Gemcitabine + Placebo"}],"paramType":"MEDIAN","populationDescription":"Subset of the intent-to-treat population: All patients randomized to treatment who achieved an objective response.","reportingStatus":"POSTED","timeFrame":"From randomization through September 17, 2010 (up to 3 years, 5 months)","title":"Duration of Objective Response (OR) as Determined by the Investigator, Per Response Evaluation Criteria for Solid Tumors (RECIST)","type":"SECONDARY","unitOfMeasure":"Months"}